ICU
SeaStar Medical Holding CorporationNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$16.65M
P/E Ratio
—
EPS
$-5.86
Beta
-1.19
52W High
$13.50
52W Low
$2.07
50-Day MA
$2.63
200-Day MA
$4.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation (ICU) is an innovative biotechnology company at the forefront of developing advanced therapies for chronic kidney disease. By harnessing proprietary technologies aimed at improving renal function and minimizing the need for invasive interventions, SeaStar addresses significant unmet medical needs within a large and growing market. With a strong emphasis on research and development, the company is well-positioned to drive progress in renal health, supported by strategic partnerships and a commitment to clinical excellence that are anticipated to accelerate the commercialization of its groundbreaking therapeutic solutions.
Fundamentals
| Revenue (TTM) | $1.23M |
| Gross Profit (TTM) | $1.18M |
| EBITDA | — |
| Operating Margin | -718.00% |
| Return on Equity | -295.10% |
| Return on Assets | -80.90% |
| Revenue/Share (TTM) | $0.59 |
| Book Value | $2.71 |
| Price-to-Book | 1.64 |
| Price-to-Sales (TTM) | 13.50 |
| EV/Revenue | 4.569 |
| EV/EBITDA | -8.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 527.00% |
| Shares Outstanding | $3.99M |
| Float | $3.95M |
| % Insiders | 2.40% |
| % Institutions | 6.36% |
Analyst Ratings
Consensus ($9.00 target)
1
Strong BuyData last updated: 4/8/2026